PUBLISHER: The Business Research Company | PRODUCT CODE: 1957511
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957511
A non-opioid pain treatment refers to therapy or medication used to manage pain without involving opioid drugs. These treatments alleviate pain through mechanisms other than opioid receptor activation and include options such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), certain antidepressants, anticonvulsants for nerve pain, as well as physical therapies like physiotherapy, exercise, heat or cold therapy, and massage.
The main product types of non-opioid pain treatments include medical cannabis, menthol-containing products, omega-3 fatty acid-containing formulations, botulinum toxins, and capsaicin-derived therapies. Medical cannabis refers to the therapeutic use of the cannabis plant or its extracts to alleviate symptoms or manage various health conditions. Drug classes used in these treatments encompass NSAIDs, acetaminophen, local anesthetics, antidepressants, anticonvulsants, corticosteroids, and others. These treatments are administered through oral, topical, injectable, and other routes and are distributed via hospital pharmacies, retail pharmacies, drugstores, and mail-order pharmacies. Common applications include orthopedic and musculoskeletal pain, postoperative pain, cancer-related pain, neuropathic pain, and other pain-related conditions.
Tariffs have impacted the non-opioid pain treatment market by raising costs of imported medical cannabis products, botulinum toxins, and specialized devices like TENS and acupuncture tools. Segments such as injectable products and high-concentration topical therapies are most affected, particularly in North America and Europe where imports are significant. While tariffs have increased costs and disrupted supply chains, they have also encouraged local manufacturing, domestic R&D, and innovation in cost-effective non-opioid pain treatments.
The non-opioid pain treatment market research report is one of a series of new reports from The Business Research Company that provides non-opioid pain treatment market statistics, including non-opioid pain treatment industry global market size, regional shares, competitors with a non-opioid pain treatment market share, detailed non-opioid pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain treatment industry. This non-opioid pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-opioid pain treatment market size has grown strongly in recent years. It will grow from $55.31 billion in 2025 to $60.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing prevalence of chronic pain conditions, growing awareness about opioid-related risks, limited availability of non-opioid alternatives, rising orthopedic and musculoskeletal procedures, increasing hospital and clinic infrastructure for pain management.
The non-opioid pain treatment market size is expected to see strong growth in the next few years. It will grow to $84.36 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to development of innovative non-opioid therapeutics, expansion of digital health monitoring and telemedicine for pain, growing adoption of combination therapies, increasing government initiatives for pain management, rising investment in personalized pain care and alternative therapies. Major trends in the forecast period include rising adoption of non-opioid pain management therapies, increased use of medical cannabis and omega-3 fatty acid supplements, growth in topical and injectable pain relief products, expansion of pain management services in hospitals and clinics, integration of non-pharmacological therapies like acupuncture and tens.
The growing number of sports-related injuries is anticipated to boost the non-opioid pain treatment market in the future. Sports-related injuries involve physical harm sustained during or following sports or exercise. This uptick stems from greater involvement in intense sports and leisure pursuits, heightening athletes' vulnerability to bodily trauma. Non-opioid pain treatments benefit these injuries by delivering potent pain alleviation and swelling reduction, sidestepping opioid-related dangers, while aiding quicker healing, better mobility, and secure ongoing care. For instance, in October 2024, Howden Group Holdings Ltd, a UK insurance intermediary, reported that Europe's top five football leagues saw 4,123 injuries in the 2023-24 season-a 4% rise from the year before. Thus, the surge in sports-related injuries is fueling expansion in the non-opioid pain treatment market.
Leading firms in the non-opioid pain treatment market are prioritizing advances in drug formulations, like non-opioid oral therapies, to ensure robust pain relief while curbing opioid-associated risks and dependency. Non-opioid oral treatments are orally taken analgesics excluding opioids, operating via distinct pathways-such as curbing inflammation, altering nerve impulses, or targeting particular receptors-to control pain absent the addiction liability or breathing issues typical of opioids. For example, in July 2025, Vertex Pharmaceuticals Incorporated, a US biotechnology firm, launched JOURNAVX, a pioneering non-opioid option for moderate-to-severe acute pain relief. This innovative therapy precisely targets pain signals, boasts an excellent safety record, and acts swiftly, promoting reliable pain mitigation, lower reliance risks, and superior patient outcomes. It facilitates precise pain control, diminishes addiction chances, and enhances recovery speed alongside life quality for those with acute pain.
In May 2025, Eli Lilly and Company, a US pharmaceutical giant, bought SiteOne Therapeutics Inc. for an undisclosed sum. Through this deal, Eli Lilly seeks to bolster its neuroscience offerings by advancing and marketing STC-004, a non-opioid Nav1.8 blocker, delivering a dependable, addiction-free solution for chronic pain. SiteOne Therapeutics Inc. is a US pharmaceutical firm specializing in non-opioid pain therapies.
Major companies operating in the non-opioid pain treatment market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Limited, Vertex Pharmaceuticals Incorporated, SUN PHARMACEUTICAL INDUSTRIES LIMITED, Perrigo Company Public Limited Company, Dr. Reddy's Laboratories, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY, Pacira BioSciences Inc, Heron Therapeutics Inc, AFT Pharmaceuticals Limited, Vivozon Pharmaceutical Co. Ltd, Levicept Ltd, Algiax Pharmaceuticals GmbH, Latigo Biotherapeutics Inc, Hyloris Pharmaceuticals SA
North America was the largest region in the non-opioid pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-opioid pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-opioid pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-opioid pain treatment market consists of revenues earned by entities by providing services such as physical therapy services, cognitive and behavioral therapies, and interventional pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-opioid pain treatment market also includes sales of antidepressants, anticonvulsants, and acupuncture kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Opioid Pain Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses non-opioid pain treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for non-opioid pain treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-opioid pain treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.